Manipulation of costimulatory pathways in autoimmune diseases

Modern Rheumatology

Volumn 11, Issue 3, 2001, Pages 184-191

  Nakajima, A ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

B7 related protein 1 inducible constimulator(B7RP 1 ICOS); CD28 B7; Costimulation programmed death ligand programmed death 1 (PD L PD1); Tumor necrosis factor and tumor necrosis factor receptor (TNF TNFR) family

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELL; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; STIMULATION; T LYMPHOCYTE ACTIVATION; THERAPY; TISSUE;

EID: 0034762206     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101650170002     Document Type: Review

References (88)

1. Costimulation and autoimmunity
2. The B7 and CD28 receptor families
3. CD28/B7 system of T cell costimulation
4. CD28-T lymphocytes: Antigenic and functional properties
5. CTLA-4 can function as a negative regulator of T cell activation
6. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
7. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
8. B7-1 and B7-2 are required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)
9. CTLA-4 regulates induction of anergy in vivo
10. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
11. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
12. CTLA-4: A negative regulator of autoimmune disease
13. B7, a B cell-restricted antigen that identifies preactivated B cells
14. Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation
15. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production
16. B70 antigen is a second ligand for CTLA-4 and CD28
17. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4
18. Requirement of CD28-CD86 costimulation in the interaction between antigen-primed T helper type 2 and B cells
19. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
20. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes
21. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses
22. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule
23. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation
24. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA4-Fc supports a key role for CD28 costimulation
25. Role of B7: CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis
26. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig
27. Treatment of murine lupus with CTLA4Ig
28. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice
29. B7-1 and B7-2 costimulatory molecules differentially activate the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
30. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
31. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: Requirement for both B7-1 and B7-2
32. Differential T cell costimulatory requirements in CD28-deficient mice
33. T-cell costimulation through B7RP-1 and ICOS
34. B7h, a novel costimulatory homolog B7.1 and B7.2, is induced by TNF-α
35. ICOS is an inducible T-cell costimulator structurally and functionally related to CD28
36. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses
37. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection
38. ICOS costimulatory receptor is essential for T-cell activation and function
39. ICOS is critical for CD40-mediated antibody class switching
40. ICOS is essential for effective T-helper-cell responses
41. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion
42. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
43. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
44. Structure and chromosomal localization of the human PD-1 gene (PDCD1)
45. The human PD-1 gene: Complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors
46. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor
47. PD-L2 is a second ligand for PD-1 and inhibits T cell activation
48. The role of CD40 in the regulation of humoral and cell-mediated immunity
49. A central role of CD40 ligand in the regulation of CD4+ T-cell response
50. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease
51. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis
52. CD40-gp39 interaction plays a critical role during allograft rejection
53. CD40 expression by human monocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40
54. Activation of human dendritic cells through CD40 cross-linking
55. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
56. High level IL-12 production by murine dendritic cells: Upregulation via MHC and CD40 molecules and downregulation by IL-4 and IL-10
57. Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by IL-12 and B7
58. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis
59. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis
60. Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells
61. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/CD40L costimulatory pathways
62. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells
63. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40)
64. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions
65. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection
66. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells
67. Control of lymphocyte function through CD27-CD70 interactions
68. CD27 is required for generation and long-term maintenance of T cell immunity
69. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: A critical role for OX40 ligand in migration, but not development, of pathogenic T cells
70. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis
71. The effect of anti-OX40 ligand antibody on the development of murine lupus
72. Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis
73. The Fas death factor
74. Fas-FasL interactions: A common pathogenic mechanism in organ-specific autoimmunity
75. The role of Fas in autoimmune diabetes
76. Essential role of the Fas ligand in the development of hepatitis
77. A role for CD95 ligand in preventing graft rejection
78. Fas ligand-induced apoptosis as a mechanism of immune privilege
79. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptas
80. Antitumor effect of locally produced CD95 ligand
81. Chemotactic activity of soluble Fas ligand against phagocytes
82. Caspase 1-independent IL-1b release and inflammation induced by the apoptosis inducer Fas ligand
83. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen
84. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis
85. Treatment of lupus in NZB/W F1 mice with monoclonal antibody against Fas ligand
86. Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice
87. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
88. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of endothelial cells